{"product_id":"isothermal-nucleic-acid-amplification-technology-market-by-product-assay-system-technology-lamp-sda-nasba-near-hda-application-diagnostics-influenza-hepatitis-ct-ng-covid-19-blood-screening-end-user-region-global-forecast-to-2028","title":"Isothermal Nucleic Acid Amplification Technology Market by Product (Assay, System), Technology (LAMP, SDA, NASBA, NEAR, HDA), Application (Diagnostics (Influenza, Hepatitis, CT\/NG, COVID-19), blood screening), End User \u0026 Region - Global Forecast to 2028","description":"\u003cp\u003eIsothermal Nucleic Acid Amplification Technology Market by Product (Assay, System), Technology (LAMP, SDA, NASBA, NEAR, HDA), Application (Diagnostics (Influenza, Hepatitis, CT\/NG, COVID-19), blood screening), End User \u0026amp; Region - Global Forecast to 2028\u003c\/p\u003e\n\n\u003cp\u003eThe isothermal nucleic acid amplification technology market is projected to reach USD 6.8 Billion by 2028 from USD 4.4 Billion in 2023, at a CAGR of 9.2% during the forecast period. Increasing prevalence of infectious diseases, launches \u0026amp; approvals for INAAT products and availability of funding for diagnostic tools are various factors projected to drive the growth of the isothermal nucleic acid amplification technology market.\u003c\/p\u003e\n\n\u003cp\u003eLAMP segment accounted for the largest share of the INAAT market\u003c\/p\u003e \n\n\u003cp\u003eBased on technology, the isothermal nucleic acid amplification technology market is segmented into loop-mediated isothermal amplification (LAMP), transcription-mediated amplification (TMA), strand displacement amplification (SDA), nicking enzyme amplification reaction (NEAR), single-primer isothermal amplification (SPIA), and other technologies. In 2022, the loop-mediated isothermal amplification (LAMP) segment dominated the market. This is owing to high demand for LAMP kits and wide availability of these kits in developed and developing markets across the globe.\u003c\/p\u003e  \n\n\u003cp\u003eInfectious disease diagnosis segment accounted for the largest application segment of the market\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications. The disease diagnosis segment is expected to dominate the market in 2022. Various factors drive the growth of the segment are rising number of HIV, influenza, and hepatitis cases across the globe, focus on infectious disease control, and use of INAAT based kits for the diagnosis of these diseases.\u003c\/p\u003e\n\n\u003cp\u003eThe prominent players in isothermal nucleic acid amplification technology market are Grifols, S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), Eiken Chemical Co., Ltd. (Japan), bioMérieux SA (France), Tecan Trading AG (Switzerland), New England Biolabs (US), QIAGEN N.V. (Germany), DiaSorin S.p.A. (Italy), General Electric (US), OptiGene Limited (UK), Quidel Corporation (US), Thermo Fisher Scientific (US), Genomtec (Poland), Mast Group Ltd. (UK), Ustar Biotechnologies (China), Jena Bioscience GmbH (Germany), Atila BioSystems (US), TwistDx Limited (UK), LGC Limited (UK), Life Sciences Advanced Technologies (US), GenoSensor Corporation (US), and PCR Biosystems (UK).?\u003c\/p\u003e\n\n\u003cp\u003e“North America: Accounted for the largest share in isothermal nucleic acid amplification technology market”\u003c\/p\u003e\n\n\u003cp\u003eNorth America has the largest share of the isothermal nucleic acid amplification technology market. Factors such as availability of research funding and the development of diagnostic industry, increasing importance of early diagnosis for patient with HIV, Hepatitis and Influenza, and developed healthcare infrastructure are the major factors driving the market growth.\u003c\/p\u003e\n\n\u003cp\u003eThe primary interviews conducted for this report can be categorized as follows:\u003c\/p\u003e\n\n\u003cp\u003eBy Respondent: Supply Side- 80% and Demand Side - 20%\u003c\/p\u003e\n\n\u003cp\u003eBy Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America -20%, Europe -15%, Asia-Pacific -55%, RoW -10%\u003c\/p\u003e\n\n\u003cp\u003eList of Companies Profiled in the Report:\u003c\/p\u003e \n\n\u003cp\u003eGrifols, S.A. (Spain)\u003c\/p\u003e\n\n\u003cp\u003eHologic, Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories (US)\u003c\/p\u003e\n\n\u003cp\u003eBecton, Dickinson and Company (US)\u003c\/p\u003e\n\n\u003cp\u003eMeridian Bioscience (US)\u003c\/p\u003e\n\n\u003cp\u003eEiken Chemical Co., Ltd. (Japan)\u003c\/p\u003e\n\n\u003cp\u003ebioMérieux SA (France)\u003c\/p\u003e\n\n\u003cp\u003eTecan Trading AG (Switzerland)\u003c\/p\u003e\n\n\u003cp\u003eNew England Biolabs (US)\u003c\/p\u003e\n\n\u003cp\u003eQIAGEN N.V. (Germany)\u003c\/p\u003e\n\n\u003cp\u003eDiaSorin S.p.A. (Italy)\u003c\/p\u003e\n\n\u003cp\u003eGeneral Electric (US)\u003c\/p\u003e\n\n\u003cp\u003eOptiGene Limited (UK)\u003c\/p\u003e\n\n\u003cp\u003eQuidel Corporation (US)\u003c\/p\u003e\n\n\u003cp\u003eThermo Fisher Scientific (US)\u003c\/p\u003e\n\n\u003cp\u003eGenomtec (Poland)\u003c\/p\u003e\n\n\u003cp\u003eMast Group Ltd. (UK)\u003c\/p\u003e\n\n\u003cp\u003eUstar Biotechnologies (China)\u003c\/p\u003e\n\n\u003cp\u003eJena Bioscience GmbH (Germany)\u003c\/p\u003e\n\n\u003cp\u003eAtila BioSystems (US)\u003c\/p\u003e\n\n\u003cp\u003eTwistDx Limited (UK)\u003c\/p\u003e\n\n\u003cp\u003eLGC Limited (UK)\u003c\/p\u003e\n\n\u003cp\u003eLife Sciences Advanced Technologies (US)\u003c\/p\u003e\n\n\u003cp\u003eGenoSensor Corporation (US)\u003c\/p\u003e\n\n\u003cp\u003ePCR Biosystems (UK)?\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a detailed picture of the isothermal nucleic acid amplification technology market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end users and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits of Buying the Report:\u003c\/p\u003e\n\n\u003cp\u003eThe report will help market leaders\/new entrants by providing them with the closest approximations of the revenue numbers for the overall isothermal nucleic acid amplification technology market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"March, 2023 \/ 226 Pages \/ MCW16235972","offer_id":47651399041330,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/isothermal-nucleic-acid-amplification-technology-market-by-product-assay-system-technology-lamp-sda-nasba-near-hda-application-diagnostics-influenza-hepatitis-ct-ng-covid-19-blood-screening-end-user-region-global-forecast-to-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}